Noticias de NERV_US

Noticias del mercado

Últimas noticias sobre NERV_US — 81 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: NERV_US ✕ 81 resultados
31/03/2026 NERV_US — Stock Titan
Federated Hermes sells 97,549 NERV shares (NASDAQ: NERV) in Form 144 notice
31/03/2026 NERV_US — Stock Titan
Federated Hermes sells 3,658 shares of NERV common stock (NASDAQ: NERV)
31/03/2026 NERV_US — Yahoo Finance
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
31/03/2026 NERV_US — GlobeNewswire
Minerva Neurosciences Announces First Patient Screened in
26/03/2026 NERV_US — MarketBeat
Minerva Neurosciences (NERV) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $NERV
25/03/2026 NERV_US — Investing News Network
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
25/03/2026 NERV_US — GlobeNewswire
Minerva Neurosciences Presents Data from its Open-label
25/03/2026 NERV_US — GlobeNewswire
Minerva Neurosciences Presents Data from its Open-label
25/03/2026 NERV_US — GlobeNewswire
Minerva Neurosciences Presents Data from its Open-label
25/03/2026 NERV_US — GlobeNewswire
Minerva Neurosciences Presents Data from its Open-label
25/03/2026 NERV_US — Yahoo Finance
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
25/03/2026 NERV_US — Stock Titan
Schizophrenia drug combo showed no safety issues as Phase 3 starts
12/03/2026 NERV_US — Investing News Network
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
12/03/2026 NERV_US — Yahoo Finance
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
12/03/2026 NERV_US — The Manila Times
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
11/03/2026 NERV_US — Yahoo Finance
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
11/03/2026 NERV_US — Stock Titan
Minerva readies 2026 trial for drug aimed at schizophrenia’s ‘negative’ symptoms
11/03/2026 NERV_US — TradingView
Minerva Neurosciences Reports $283.7M Q4 Net Loss; $82.4M Cash at Year-End
11/03/2026 NERV_US — Via Ritzau
Minerva Neurosciences, Inc
04/03/2026 NERV_US — Yahoo Finance
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference

Página 4 de 5

keyboard_arrow_up